VistaJet announces new partnership with maverick Burgundy winemaker Olivier Bernstein 20-09-2023, 16:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Cool Company Ltd. concludes regulatory review process for 11-03-2023, 05:38